Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02438995 · ClinicalTrials.gov registry record · Phase 1
Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck
A Phase 1 study, sponsored by Northwell Health.
- Terminated
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT02438995 is a Phase 1 study that was terminated before completion, run by Northwell Health. The registered enrollment target is 11 participants.
The verdict
NCT02438995, a Phase 1 study, was terminated before completion, sponsored by Northwell Health.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
This is an open-label, non-randomized, two arm, Phase I research study of superselective intraarterial Cetuximab (Erbitux) with or without radiation therapy for treatment of recurrent unresectable squamous cell carcinoma of the head and neck (HNSCC).
Interventions
- DRUG Intraarterial Cetxuimab (Erbitux)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2015-05 |
| Est. Completion | 2021-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02438995
The ClinicalTrials.gov registry entry for NCT02438995 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Intraarterial Cetxuimab (Erbitux) is the first listed.
NCT02438995 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02438995 about?
NCT02438995 is a clinical study titled "Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck". This is an open-label, non-randomized, two arm, Phase I research study of superselective intraarterial Cetuximab (Erbitux) with or without radiation therapy for treatment of recurrent unresectable squamous cell carcinoma of the head and neck (HNSCC).
What is the current status of trial NCT02438995?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2015-05. Estimated completion is 2021-06.
What interventions are being tested in trial NCT02438995?
The interventions under investigation include: Intraarterial Cetxuimab (Erbitux) (DRUG).
Who is sponsoring clinical trial NCT02438995?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.